Article ID Journal Published Year Pages File Type
6200162 Ophthalmology 2016 8 Pages PDF
Abstract
Intravitreal E10030 administered at doses up to 3 mg in combination with ranibizumab was well tolerated without evidence of systemic or ocular toxicity in participants with NVAMD. The changes in both mean VA and imaging biomarkers suggest a favorable short-term safety profile for the combination therapy of E10030 and ranibizumab.
Related Topics
Health Sciences Medicine and Dentistry Ophthalmology
Authors
, , , , , ,